Eurobio Scientific
Diaxonhit | Specialty Diagnostic Solution.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | N/A | IPO | |
| Total Funding | 000k | ||
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 220 % | (3 %) | (17 %) | (14 %) | 19 % | (11 %) | 9 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 47 % | 42 % | 27 % | 21 % | 19 % | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 39 % | 33 % | 16 % | 4 % | 3 % | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 1 % | 2 % | 2 % | 5 % | 3 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Eurobio Scientific is a French company specializing in the discovery, development, and commercialization of specialty diagnostic solutions and life science products. The company serves a diverse range of clients, including healthcare providers, research institutions, and laboratories. Operating primarily in the in vitro diagnostics market, Eurobio Scientific offers a comprehensive portfolio of instruments and reagents, with a notable focus on infectious diseases such as Covid-19. The business model revolves around the development and sale of proprietary diagnostic tests, including the EBX 041 SARS CoV 2 test, which is licensed from the Institut Pasteur and manufactured in-house. Revenue is generated through the sale of these diagnostic products and related services. Eurobio Scientific has also invested in digital tools and a new ERP system to support its growing operations and ensure customer satisfaction.
Keywords: specialty diagnostics, life sciences, infectious diseases, proprietary tests, in vitro diagnostics, healthcare providers, research institutions, Covid-19, digital tools, ERP system.
Tech stack
Investments by Eurobio Scientific
Edit
